PatentJul 1, 2026, 07:01 AM
INmune Bio Files CORDStrom™ Patent in US, Securing IP to 2045
AI Summary
INmune Bio, Inc. has submitted its CORDStrom™ platform patent application into the U.S. national phase before the USPTO. This move is a key element of the company's global intellectual property strategy for its next-generation mesenchymal stromal cell platform, including Ebstrocel for epidermolysis bullosa. If granted, this foundational patent family is projected to provide exclusive commercial protection extending into at least 2045, following a favorable PCT Written Opinion. The company also plans to pursue corresponding patent protection in other strategic jurisdictions worldwide.
Key Highlights
- CORDStrom™ platform patent application advanced to U.S. national phase.
- Patent aims to protect Ebstrocel for epidermolysis bullosa and next-gen modalities.
- Favorable PCT Written Opinion received, validating novelty and inventiveness.
- If granted, patent protection expected to extend into at least 2045.
- Company plans global expansion of patent strategy in UK, Europe, Asia, Latin America.
- Patent covers composition-of-matter and method-of-treatment claims.
- CORDStrom™ platform addresses donor variability and manufacturing inconsistencies.
Price Impact
More from INMB